Antimicrobial testing is crucial for managing ventilator-associated and hospital-acquired pneumonia, with results empowering physicians to appropriately prescribe and manage antibacterial selection, according to research presented at the American College of Chest Physicians (CHEST) Annual Meeting, held October 18 to 21, 2026, in Phoenix, Arizona.
At CHEST, Marcos Restrepo, MD, PhD, FCCP, presented the latest updates in clinical guidelines for managing these conditions. The current guideline framework focuses on patients who are critically ill, “very sick, on mechanical ventilation for more than 48 hours, with fever, purulent sputum…and a new pulmonary infiltrate,” said Dr Restrepo. But because much of the biomarker data come from patients on mechanical ventilation, which can simplify pathogen sampling, “there is a big extrapolation to all of the patients with hospital-acquired pneumonia who are not ventilated.”
A recent analysis of 24 published studies showed that the primary pathogen targets in critically ill patients on mechanical ventilation are gram-negative bacteria — such as Pseudomonas aeruginosa and pathogens in the Acinetobacter baumannii group — rather than anaerobic flora. When considering antibacterial stewardship, it’s important to cover gram-negative rods, including Pseudomonas aeruginosa and Acinetobacter. Gram-positive pathogens, Dr Restrepo noted, are primarily MRSA.
The duration of antimicrobial therapy needs to be placed in the context of how the patient is improving and how different biomarkers and diagnostic tests behave.
While there is a consensus in the literature on which targets should be the focus of antibiotic therapy, guidelines from the American Thoracic Society/Infectious Diseases Society of America and the European Respiratory Society/European Society of Intensive Care Medicine/European Society of Clinical Microbiology and Infectious Diseases differ. The biggest difference, Dr Restrepo noted, surrounds risk stratification: guidelines from the United States emphasize organ failure as a predictor, while the European guidelines favor monotherapy against Pseudomonas in non-septic shock scenarios.
“Most of the time, we don’t know what pathogens a patient has,” said Dr Restrepo. “Therefore, we are going to rely on the most likely possibilities.” These possibilities include persistent pathogens or a high risk of antibiotic resistance, as well as risk factors such as use of antibiotic therapy within the previous 90 days. Among patients with hospital-acquired pneumonia who are not on mechanical ventilators, clinicians should use at least 1 broad-spectrum antibiotic covering Pseudonomas. If ventilator-associated pneumonia is suspected, and the patient has acute respiratory distress syndrome (ARDS) or septic shock, a broad-spectrum antibiotic should be used. If the patient does not have ARDS or septic shock, consider the risk factors: “if risk factors are present or absent, you need to expand your coverage,” Dr Restrepo said.
A randomized controlled trial conducted in Canada previously suggested no difference between looking at endotracheal aspirate vs bronchoalveolar lavage, a recommendation that was “very important for low resource settings where you may not have a bronchoscope available in the middle of the night to do a bronchoscopy evaluation to obtain the sample from the deeper airway,” Dr Restrepo said. Conversely, European guidelines recommend antibiotic monotherapy, unless the patient is in septic shock — in which case, dual-therapy is appropriate.
“With rapid testing, we can tailor this therapy much faster,” said Dr Restrepo. “We don’t need to keep patients on the same antibiotic for a long period of time, and we might consider how to deescalate and reduce the duration of therapy.”
Several strategies for therapeutic deescalation are available. “One approach is waiting until the cultures tell us, ‘It’s growing Pseudomonas, let’s change therapies,’” said Dr Restrepo.
When it comes to therapeutic deescalation, 7 or 8 days of therapy is usually appropriate — despite what clinical practice suggests. “It’s very difficult to change this approach, despite the evidence and the recommendation strength,” Dr Restrepo said. “This recommendation needs to be placed in the context of how the patient is doing, what’s going on with laboratory parameters, and if [there are] any other biomarkers that were high and are coming down.”
However, treatment length depends on the pathogen being treated. For highly resistant pathogens — such as lactose-fermenting gram-negative rods — patients may have a recurring, worsening infection.
Over a 10-year period, multiple randomized controlled trials compared new antibiotics with current best available therapies. These studies, many of which were double-blind, noninferiority trials, showed similar between-group outcomes.
“Even in the best case scenario, with all the new antibiotics available, the clinical cure rate is never above 75% in both groups,” said Dr Restrepo. “When you’re going to utilize a newer antibiotic — no matter how new it is — you need to do antimicrobial testing.”
“The clinical practice guidelines offer an initial empiric approach,” he added. “We don’t know what the pathogen is going to be, and we are trying to assess all the different risk factors, and the likelihood that these patients are going to have a pathogen that is resistant or difficult to treat.”
He concluded, “The duration of antimicrobial therapy needs to be placed in the context of how the patient is improving and how different biomarkers and diagnostic tests behave.”